Drug Invention Today
ISSN NO: 0975-7619
Drug Invention Today (DIT) was first published in 2009 by JPR Solutions. It is a journal, which publishes reviews, research papers and short communications . 
• Novel Drug Delivery Systems • Nanotechnology & Nanomedicine • Biotechnology related pharmaceutical technology • Polymeric bio-conjugates • Biological macromolecules • Biomaterials • Drug Information • Drug discovery/development • Screening of drugs from natural & synthetic origins • Novel therapeutic strategies • Combinatorial chemistry and parallel synthesis • Clinical trials • Case Reports
 Impact FactorTM ( India ) = 0.897 as on date (08.05.2017)
  Scopus Indexed ( link http://www.scimagojr.com/journalsearch.php?q=21100202909&tip=sid&clean=0)
Journal Metrics for this   Drug Invention Today (Source ID: 21100202909): 2014 (SNIP) Source Normalized Impact Per Paper : 0.402; SCImago Journal Rank (SJR):0.301; Impact Per Publication : 0.517 (Top level : Life Science)
Indexed in
NCBI NLM Catalogue,
SCOPUS, EMBASE (Elsevier),
SCIMAGO, CAS,
ROAD, CABI, Google Scholar,
Open J-Gate, Biblioteca,
Science Central,
Index Scholar, Indian Citation Index,
 AYUSH Research Portal, 
Indexed Copernicus, EBSCO, PSOAR,
Ulrichs Directory of Periodicals, etc.

Manuscripts Published

Journal: Drug Invention Today , Volume: 2, Issue: 6.
Article Id: JPRS-D(DD)-0000939
Title: In Vitro - In Vivo Correlation: A Review
Category: Drug (Discovery/Development)
Section: Review Article
Country: India
View Article

Correlation between in vitro and in vivo data have long been sought in biopharmaceutical as a mean of modeling the human organism and thereby monitor and optimize the dosage form with the fewest possible trial in man. One of the challenge of biopharmaceutics research is correlating in vitro drug release (dissolution) information of various types of drug formulations to the in vivo drug profile and to provide a regulatory perspective on its utility in product development and optimization. A successful correlation can assist in selection of appropriate dissolution acceptance and can be used as a surrogate for in vivo bioavailability and to support biowaivers. It can also assist in quality control for certain scale-up and post approval changes (SUPAC). With the proliferation of modified-release products, it becomes necessary to examine the concept of In vitro-In vivo Correlation (IVIVC) in greater depth. Investigations of IVIVC are increasingly becoming an integral part of extended release drug development. In addition, the Biopharmaceutical Classification System provides a science-based guidance on solubility and permeability drug issues, which are indicators of predictive IVIVC. The aim of this review article is to represents the various notions of IVIVC and its applications, Biopharmaceutical classification systems (BCS) & application of BCS in IVIVC development, Various type of dissolution media and their importance and methodology of dissolution have been highlighted.

Journal: Drug Invention Today , Volume: 2, Issue: 6.
Article Id: JPRS-PS-0000940
Title: In vitro and in vivo antioxidant activity of Phyllanthus reticulatus
Category: Pharmacological Screening
Section: Research Article
Country: India
View Article

Many plants possess antioxidant ingredients that provided efficacy by additive or synergistic activities. Phyllanthus reticulatus plant was a strong astringent, used for the treatment of liver, spleen diseases and rheumatism. Antioxidant activity of the methanol crude extract of entire plant of P. reticulatus was assessed using DPPH, superoxide anion and metal chelating assays at different concentrations. The potent extract of P. reticulatus was tested for in vivo efficacy. The methanol extract exhibited potent antioxidant activity compared to known antioxidant. In vivo studies on potent extract of P. reticulatus demonstrated dose dependent reduction in hepatic malondialdehyde (330.70, 279.40 and 383.79μMmg-1 protein) with simultaneous improvement in hepatic glutathione (7.03, 18.16
and 6.88μgmg-1 protein) and catalase levels (678.10, 787.00 and 522.00μgmg-1 protein) respectively for 50, 100mgkg-1 doses and control) compared to control group. Duet to its natural origin and potent free radical scavenging ability P. reticulatus could be used as a potential preventive intervention for free radical mediated diseases.

Journal: Drug Invention Today , Volume: 2, Issue: 6.
Article Id: JPRS-MSNS-0000941
Title: Antimicrobial activity of the crude extracts of Chlorophycean seaweeds Ulva, Caulerpa and Spongomorpha sps. against clinical and phytopathogens
Category: Microbiological Study (on Natural/ Synthetic drug)
Section: Research Article
Country: India
View Article

Marine organisms are a rich source of structurally novel and biologically active metabolites. As a result of evolving resistance of microorganisms to existing antibiotics, there is an increasing need for newer antibiotics, the present study was carried out to investigate the antimicrobial potentiality of the marine Chlorophycean algae Ulva lactuca, Caulerpa taxifolia and Spongomorpha indica against six strains of Gram positive, Gram negative bacteria and Fungal organisms that cause diseases and disorders in man, animals and plants. Crude extracts revealed a wide range of antimicrobial activity against tested pathogens and further bacterial strains were more sensitive to the seaweed extracts when compared to the fungal organisms. The overall antimicrobial activity assessed from the above results indicates the presence of active constituents in the extractions of seaweeds which can be exploited for the production of lead molecules which are of use in pharmaceutical industry.